Safety, Tolerability, and Preliminary Effectiveness of CTH120 in Fragile X Syndrome | ClinicalTrials HQ

Ask about research services

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
Safety, Tolerability, and Preliminary Effectiveness of CTH120 in Fragile X Syndrome	Congenital Abnormalities, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Disease Attributes, Neurobehavioral Manifestations, Neurologic Manifestations, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Rare Diseases, Sex Chromosome Disorders, Signs and Symptoms, X-linked disease, central nervous system disorder, chromosomal disorder, fragile X syndrome, hereditary disease, inherited neurodegenerative disorder, intellectual disability, nervous system disorder, neurodevelopmental disorder, psychiatric disorder	Recruiting	Phase 2	2026-07-17		NCT07654114

5 results · Page 1 of 1

Swipe the table sideways for more columns.

Organizations	Linked trials
Astrum CRO, S.L.	4
Connecta Therapeutics, S.L.	1
Corporacion Parc Tauli	20
Hospital del Mar Research Institute (IMIM)	19
Ministry of Science and Innovation, Spain	6

2 results · Page 1 of 1

Swipe the table sideways for more columns.

Research sites	City	Country	Linked trials
Consorci Corporació Sanitaria Parc Taulí. Institut Investigació i Innovació Parc Taulí (I3PT)	Sabadell	Spain	1
Hospital del Mar Medical Research Institute	Barcelona	Spain	1